Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Scalp psoriasis seriously affects the appearance and psychological status of patients. The aim of this study was to investigate the effect and potential mechanism of RPL9 and TIFA in scalp psoriasis, so as to provide a precise and effective way for the clinical treatment of scalp psoriasis.
Methods: The Gene Expression Omnibus (GEO) database was employed to download the GSE75343 dataset to search for differentially expressed genes (DEGs) in scalp psoriasis through Sangerbox. Gene set enrichment analysis (GSEA) and gene set variation analysis (GSVA) enrichment analysis, functional enrichment analysis, immune cell infiltration analysis, immune responses and correlation analysis with 12 hub genes were performed. Then, STRING was used to develop a protein-protein interaction (PPI) network, used Cytoscape to locate hub genes, and SVM-RFE and random forest were utilized to identified RPL9 as the targeted gene. TIFA-RPL9 interaction predictions were made viathe Open Targets Platform and Uniprot. Further, the RPL9 and TIFA expression, molecular mechanism, and function were assessed in scalp psoriasis.
Results: Immunohistochemistry, qPCR, and western blotting verified that RPL9 and TIFA were highly expressed in lesional tissues of scalp psoriasis and IL17A-stimulated HaCaT cells. RPL9 knockdown effectively suppressed the proliferative capacity of IL17A-stimulated HaCaT cells in the CCK8 assay. The co-immunoprecipitation results revealed that RPL9 could interact with TIFA in IL17A-stimulated HaCaT cells. In qPCR and western blotting, RPL9 knockdown significantly inhibited TIFA at the mRNA and protein levels in IL17A-stimulated HaCaT cells. In ELISA, the secretion of TNF-α was markedly inhibited after downregulating RPL9 in IL17A-stimulated HaCaT cells.
Conclusion: To our knowledge, we have elucidated the expression and role of RPL9 and TIFA in scalp psoriatic skin and keratinocytes, and our findings confirm that RPL9 might act as a candidate therapeutic target for scalp psoriasis.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.gene.2023.147918 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Factors influencing the transition time from psoriasis to psoriatic arthritis: a real-world multicenter analysis.
Rheumatol Int
September 2025
Division of Rheumatology and Immunology, Department of PMR, , Sakarya University School of Medicine, Sakarya, Turkey.
To identify clinical and demographic predictors associated with the timing of transition from psoriasis (PsO) to psoriatic arthritis (PsA), and to compare the characteristics of patients with concurrent PsO-PsA onset versus those with prolonged transition. A multi-center, observational study was conducted using data from the Turkish League Against Rheumatism (TLAR) network including PsA patients fulfilling CASPAR criteria. Patients were categorized into two groups: Group 1 (concurrent PsO and PsA onset within ± 1 year) and Group 2 (prolonged transition to PsA, > 1 year after PsO).
View Article and Find Full Text PDFApremilast treatment of immune-mediated inflammatory skin diseases: a narrative review.
Front Pharmacol
August 2025
Department of Dermatology, Zhongshan Second People's Hospital, Zhongshan, Guangdong, China.
Novel therapeutic approaches on molecular pathways are being developed to treat inflammatory and autoimmune cutaneous dermatoses. Apremilast is an orally administered small-molecule phosphodiesterase 4 (PDE4) inhibitor that upregulates intracellular cyclic 3',5'-adenosine monophosphate (cAMP) levels to mediate a large array of proinflammatory cytokines as well as exerts its anti-inflammatory functions and therapeutic efficacy in skin diseases rather than an immunosuppressive mode of action. Early-phase clinical trials have demonstrated its favorable efficacy such that the United States Food and Drug Administration (USFDA) has approved its use for the treatment of psoriasis, psoriatic arthritis, and Behçet's syndrome.
View Article and Find Full Text PDFMisdiagnosis of crusted scabies as psoriasis: a case study.
J Parasit Dis
September 2025
Department of Dermatology, Medical School of Oujda, Mohammed VI University Hospital of Oujda, Mohammed First University of Oujda, Oujda, Morocco.
This paper presents a case of a 43-year-old man with Down syndrome misdiagnosed with psoriasis, later diagnosed with CS. Clinical manifestations included pruritus, hyperkeratotic plaques, and yellow crusts on the scalp, hands, and feet. Laboratory findings revealed eosinophilia and confirmed scabies through mite identification.
View Article and Find Full Text PDFTrichoscopic Features of Scalp Psoriasis: Their Association With Disease Severity and Quality of Life in a Hispanic Population.
Int J Dermatol
September 2025
Department of Dermatology, Universidad Autónoma de Nuevo Leon, University Hospital "Dr. José Eleuterio González", Monterrey, Nuevo León, México.
Background: Scalp psoriasis is a common condition that impairs quality of life (QoL). Trichoscopy is a valuable tool for diagnosis, but its correlation with disease severity or patient-reported outcomes, especially in Hispanic populations, remains unclear due to limited data. This study aimed to characterize the trichoscopic findings of scalp psoriasis in a Hispanic cohort and to evaluate their association with clinical severity and QoL measures.
View Article and Find Full Text PDFCase Report: Severe psoriasis skin lesions following ofatumumab treatment for multiple sclerosis.
Front Immunol
August 2025
Department of Dermatology, Venereology and Allergology, Faculty of Medicine, Medical University of Gdansk, Gdansk, Poland.
The article explores a case study of a patient diagnosed with relapsing-remitting multiple sclerosis (RRMS) who, while receiving treatment with the anti-CD20 monoclonal antibody ofatumumab, developed psoriatic skin lesions. Initially, sharply demarcated, scaly, erythematous lesions were observed only in the anogenital area. After several weeks, additional lesions appeared on the ear lobes, scalp, and lower legs following subsequent administrations of ofatumumab.
View Article and Find Full Text PDF